Activating Compound | Comment | Organism | Structure |
---|---|---|---|
ERK | heregulin-mediated HAS isozyme phosphorylation/activation | Homo sapiens |
Application | Comment | Organism |
---|---|---|
medicine | heregulin activation of ErbB2-ERK signaling modulates HAS phosphorylation/activation and hyaluronan production leading to CD-44-mediated oncogenic events and ovarian cancer progression | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
the human HAS2 expression plasmid is prepared by inserting its coding sequence into the vector pcDNA 3.1/CT-GFP-TOPO | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
AG825 | ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ErbB2 inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation | Homo sapiens | |
siRNA | - |
Homo sapiens | |
thiazolidinedione | ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation; ERK inhibitor, blocks the heregulin-mediated HAS isozyme phosphorylation/activation | Homo sapiens |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
60000 | - |
determined by SDS-PAGE and Western Blot analysis | Homo sapiens |
62000 | - |
determined by SDS-PAGE and Western Blot analysis | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
UDP-alpha-D-glucuronate + N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-[nascent hyaluronan] | Homo sapiens | - |
UDP + beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-[nascent hyaluronan] | - |
? | |
UDP-alpha-N-acetyl-D-glucosamine + beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-[nascent hyaluronan] | Homo sapiens | - |
UDP + N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-[nascent hyaluronan] | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q92819 | sequence used for preparation of siRNA | - |
Homo sapiens | Q92839 | sequence used for preparation of siRNA | - |
Homo sapiens | Q96RV2 | sequence used for preparation of siRNA | - |
Posttranslational Modification | Comment | Organism |
---|---|---|
phosphoprotein | ERK-mediated phosphorylation | Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HEK-293 cell | - |
Homo sapiens | - |
ovary cancer cell | - |
Homo sapiens | - |
SKOV-3 cell | SKOV-3.ipl cell, the cell line is established from ascites that developed in a nu/nu mouse given an intraperitoneal injection of SK-OV-3 human ovarian carcinoma cell line | Homo sapiens | - |
SKOV-3 cell | the SK-OV-3.ipl cell line is established from ascites that developed in a nu/nu mouse given an intraperitoneal injection of SK-OV-3 human ovarian carcinoma cell line | Homo sapiens | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
0.0000000062 | - |
HAS activity, HAS1siRNA + HAS2siRNA + HAS3siRNA treatment, plus heregulin | Homo sapiens |
0.0000000092 | - |
HAS activity, HAS1siRNA + HAS2siRNA + HAS3siRNA treatment | Homo sapiens |
0.000000017 | - |
HAS activity, HAS2siRNA treatment | Homo sapiens |
0.0000000175 | - |
HAS activity, HAS1siRNA treatment | Homo sapiens |
0.0000000188 | - |
HAS activity, HAS3siRNA treatment | Homo sapiens |
0.0000000222 | - |
HAS activity, AG825 treatment | Homo sapiens |
0.0000000227 | - |
HAS activity, HAS2siRNA treatment, plus heregulin | Homo sapiens |
0.000000023 | - |
HAS activity, thiazolidinedione treatment | Homo sapiens |
0.0000000233 | - |
HAS activity, no treatment, control | Homo sapiens |
0.0000000237 | - |
HAS activity, scrambled sequence treatment, control | Homo sapiens |
0.0000000248 | - |
HAS activity, HAS1siRNA treatment, plus heregulin | Homo sapiens |
0.000000025 | - |
HAS activity, HAS3siRNA treatment, plus heregulin | Homo sapiens |
0.0000000257 | - |
HAS activity, AG825 treatment, plus heregulin | Homo sapiens |
0.0000000263 | - |
HAS activity, thiazolidinedione treatment, plus heregulin | Homo sapiens |
0.0000000583 | - |
HAS activity, scrambled sequence treatment, control, plus heregulin | Homo sapiens |
0.0000000627 | - |
HAS activity, no treatment, control, plus heregulin | Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
UDP-alpha-D-glucuronate + N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-[nascent hyaluronan] | - |
Homo sapiens | UDP + beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-[nascent hyaluronan] | - |
? | |
UDP-alpha-N-acetyl-D-glucosamine + beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-[nascent hyaluronan] | - |
Homo sapiens | UDP + N-acetyl-beta-D-glucosaminyl-(1-4)-beta-D-glucuronosyl-(1-3)-N-acetyl-beta-D-glucosaminyl-(1-4)-[nascent hyaluronan] | - |
? |
Synonyms | Comment | Organism |
---|---|---|
HAS1 | - |
Homo sapiens |
Has2 | - |
Homo sapiens |
Has3 | - |
Homo sapiens |
hyaluronan synthase | - |
Homo sapiens |